Tutogen Medical, Inc. Reports Second Quarter Fiscal 2005 Financial Results

Tutogen Medical, Inc. Reports Second Quarter Fiscal 2005 Financial Results
May 11, 2005
Tutogen Medical, Inc.
WEST PATERSON, N.J., May 5 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. , a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, will report financial results for the second quarter ended March 31, 2005 on Wednesday, May 11, 2005. The Company will discuss these results in a conference call scheduled for 4:15 p.m. ET, May 11, 2005.
Interested parties can access the call by dialing (877) 407-9205 or (201) 689-8054 or by accessing the web cast at http://www.tutogen.com/investor.asp. A replay of the call will be available at (877) 660-6853 or (201) 689-8055, account number 286 and access number 150314 for 7 days following the call, and the web cast can be accessed at http://www.tutogen.com/investor.asp for 30 days.
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process(R) of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The CompanyÇƒÙs Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc., the Mentor Corporation, IOP, Inc. and through independent distributors and subsidiaries in the U.S. and Germany. For more information, visit the CompanyÇƒÙs Web site at http://www.tutogen.com/.
For the quarter the Company reported revenues of $7.6 million compared to $7.1 million in the comparable quarter last year; an increase of 7 percent. Net loss for the quarter was $1.2 million, or $(0.08) per share on a fully diluted basis, compared to net income of $653,000, or $0.03 per fully diluted share, in the second fiscal quarter last year.
For the six-month period the Company reported revenues of $14.6 million compared to $14.6 million in the comparable period last year. Net loss for the first half of fiscal 2005 was $2.6 million, or $(0.16) per share on a fully diluted basis, compared to net income of $1.2 million, or $0.07 per fully diluted share, in the first half of fiscal 2004.
Guy L. Mayer, chief executive officer of Tutogen Medical, said, Çƒ?During the first six months of this fiscal year our dental segment continued to grow at an accelerated rate, by posting an 89 percent sales increase compared to the first half of last year. During the quarter we commenced a number of initiatives to address the shortfall in sales in our international markets and other U.S. market segments. We have a number of strong distribution partners and we are confident that working closely with them we can accelerate sales of our leading-edge product portfolio.Çƒ?
For the quarter the Company reported revenues of $7.6 million compared to $7.1 million in the comparable quarter last year; an increase of 7 percent. Net loss for the quarter was $1.2 million, or $(0.08) per share on a fully diluted basis, compared to net income of $653,000, or $0.03 per fully diluted share, in the second fiscal quarter last year.
For the six-month period the Company reported revenues of $14.6 million compared to $14.6 million in the comparable period last year. Net loss for the first half of fiscal 2005 was $2.6 million, or $(0.16) per share on a fully diluted basis, compared to net income of $1.2 million, or $0.07 per fully diluted share, in the first half of fiscal 2004.
Guy L. Mayer, chief executive officer of Tutogen Medical, said, Çƒ?During the first six months of this fiscal year our dental segment continued to grow at an accelerated rate, by posting an 89 percent sales increase compared to the first half of last year. During the quarter we commenced a number of initiatives to address the shortfall in sales in our international markets and other U.S. market segments. We have a number of strong distribution partners and we are confident that working closely with them we can accelerate sales of our leading-edge product portfolio.Çƒ?
For the quarter the Company reported revenues of $7.6 million compared to $7.1 million in the comparable quarter last year; an increase of 7 percent. Net loss for the quarter was $1.2 million, or $(0.08) per share on a fully diluted basis, compared to net income of $653,000, or $0.03 per fully diluted share, in the second fiscal quarter last year.
For the six-month period the Company reported revenues of $14.6 million compared to $14.6 million in the comparable period last year. Net loss for the first half of fiscal 2005 was $2.6 million, or $(0.16) per share on a fully diluted basis, compared to net income of $1.2 million, or $0.07 per fully diluted share, in the first half of fiscal 2004.
Guy L. Mayer, chief executive officer of Tutogen Medical, said, Çƒ?During the first six months of this fiscal year our dental segment continued to grow at an accelerated rate, by posting an 89 percent sales increase compared to the first half of last year. During the quarter we commenced a number of initiatives to address the shortfall in sales in our international markets and other U.S. market segments. We have a number of strong distribution partners and we are confident that working closely with them we can accelerate sales of our leading-edge product portfolio.Çƒ?